18F-D4-FCH in mCRPC
Research type
Research Study
Full title
Investigation of changes in tumour choline metabolism in metastatic castrate resistant prostate cancer patients treated with novel anti-androgens.
IRAS ID
202727
Contact name
Suraiya Dubash
Contact email
Sponsor organisation
Imperial college Healthcare
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
This will be a non-randomized observational study, performed in patients with metastatic castrate resistant prostate cancer (mCRPC) who are fit for Abiraterone or Enzalutamide. These drugs are already available to mCRPC patients having been approved by NICE or through the cancer drugs fund (CDF). Previous treatment with chemotherapy will be allowed. The study will image 12 patients. Three PET scans will be performed – at baseline, at 4-6 weeks after commencement of treatment (to differentiate flare phenomenon vs. true progression) and at 3-4 months after start of treatment. We will assess choline uptake at these various time-points. The results of study will hopefully allow for a further larger study in the future.
REC name
South East Scotland REC 02
REC reference
16/SS/0145
Date of REC Opinion
16 Sep 2016
REC opinion
Further Information Favourable Opinion